{"entity":{"id":"nct01020448","kind":"trial","name":"Effect of Triptorelin (Decapeptyl®) 22.5 mg on Two Biomarkers in Patients With Advanced Prostate Cancer","aka":[],"tldr":"A phase 3 trial of Triptorelin in Prostate cancer, run by Ipsen, completed.","summary":"Effect of Triptorelin (Decapeptyl®) 22.5 mg on Two Biomarkers in Patients With Advanced Prostate Cancer is a phase 3 interventional study registered as NCT01020448 by Ipsen, with 339 participants recorded, started 2009-11 and reaching its primary completion in 2011-11. Interventions recorded: Triptorelin (Decapeptyl®). Conditions recorded: Prostate Cancer.\n\nLinked to the drug Triptorelin because the registry names it among its interventions and Prostate cancer among its conditions. Registry record only: no result has been read by an editor.","status":"completed","asOf":"2026-09-22","links":[{"label":"ClinicalTrials.gov NCT01020448","url":"https://clinicaltrials.gov/study/NCT01020448"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["prostate"],"sections":[],"technologies":[],"targets":[],"drugs":["triptorelin"],"companies":["ipsen"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT01020448","phase":"3","setting":"Prostate Cancer Antigen-3 (PCA-3) and TMPRSS2-ERG (T2-ERG) Score Changes During Initiation of Androgen Deprivation Therapy (ADT) With Triptorelin 22.5mg in Patients With Advanced Prostate Cancer (PCA): A Phase III, Single Arm Multicentre Study","sponsor":"Ipsen","enrolled":339,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct01020448/","neighbours":{"cancer":[{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"drug":[{"id":"triptorelin","kind":"drug","name":"Triptorelin","route":"/drugs/triptorelin/"}],"company":[{"id":"ipsen","kind":"company","name":"Ipsen","route":"/companies/ipsen/"}]}}